Abstract
Mineralocorticoid Receptor Antagonists (MRAs) reduce mortality and improve LV ejection fraction in patients with systolic heart failure. However, the impact of MRAs on cardiac function during Continuous Flow Left Ventricular Assist Device (CF LVAD) support remains unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
